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Background: The evidence of undertreatment of pain in patients with dementia is inconsistent. This may largely be
due to methodological differences and shortcomings of studies. In a large cohort of patients with incident
dementia and age- and sex-matched controls we examined (1) how often they receive diagnoses indicating pain,
(2) how often they receive analgesics and (3) in which agents and formulations.
Methods: Using health insurance claims data we identified 1,848 patients with a first diagnosis of dementia
aged≥ 65 years and 7,385 age- and sex-matched controls. We analysed differences in diagnoses indicating pain
and analgesic drugs prescribed between these two groups within the incidence year. We further fitted logistic
regression models and stepwise adjusted for several covariates to study the relation between dementia and
analgesics.
Results: On average, patients were 78.7 years old (48% female). The proportions receiving at least one diagnosis
indicating pain were similar between the dementia and control group (74.4% vs. 72.5%; p = 0.11). The proportion
who received analgesics was higher in patients with dementia in the crude analysis (47.5% vs. 44.7%; OR: 1.12;
95% CI: 1.01-1.24), but was significantly lower when adjusted for socio-demographic variables, care dependency,
comorbidities and diagnoses indicating pain (OR: 0.78; 95% CI: 0.68-0.88). Analgesics in liquid form such as
metamizole and tramadol were more often used in dementia.
Conclusions: Our findings show a comparable documentation of diagnoses indicating pain in persons with
incident dementia compared to those without. However, there still seems to be an undertreatment of pain in
patients with dementia. Irrespective of dementia, analgesics seem to be more often prescribed to sicker patients
and to control pain in the context of mobility.
Keywords: Dementia, Comorbidity, Health services research, Pain, AnalgesicsBackground
Pain is a common symptom in older persons. Findings
from clinical and experimental studies show that pain in
patients with dementia is as frequent and intense as in
patients without dementia, even if less reported [1]. De-
mentia guidelines often mention pain as a possible cause
of ‘Behavioral and Psychological Symptoms of Dementia’
(BPSD) [2,3]. A recently published study showed that an
appropriate treatment of pain in nursing home residents* Correspondence: hoffmann@zes.uni-bremen.de
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reproduction in any medium, provided the ormay reduce the incidence of agitation and neuropsychi-
atric symptoms [4].
However, there is evidence that pain in dementia may
remain undetected due to difficulties in communication
[5-8]. Along with problems of detection, there is inconsist-
ent evidence of undertreatment of pain in patients with
dementia. Some studies found a lower proportion of pain-
killers prescribed for dementia patients [8-13], others
show no differences for (strong) pain medication [14-16]
or even more frequent use in cognitively impaired patients
[17]. Haasum et al. show higher use of paracetamol (acet-
aminophen) in persons with dementia and no differences
in the use of any analgesics, opioids and NSAIDs afterral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as a possible reflection of an ‘increased awareness of pain
and pain management in persons with dementia’ in com-
parison to older studies [17]. A recent Finnish study in
turn showed partially different results. There, dementia
patients were given fewer opioids, but more often strong
opioids (especially fentanyl) [18].
The diverging results of the cited studies may largely be
due to methodological differences and shortcomings. The
two more recent Scandinavian studies were population
based with a high number of included patients [17,18]. All
the other studies refer to much smaller, mostly nursing
home based populations [8-16]. Most studies investigated
the use of only some painkiller groups (e.g. only opioids)
and all studies included prevalent dementia patients, i.e.
dementia patients in very different stages of the disease.
The aim of this study was to investigate in a large co-
hort of newly diagnosed dementia patients compared to
age- and sex-matched controls
 the occurrence of pain (and types of diagnoses
indicating pain),
 the prescribing of analgesics (and which agents and
formulations) and
 factors associated with the prescription of analgesics
within the incidence year.
Methods
Design and study population
For this study, we used pseudonymized claims data of
the Gmünder ErsatzKasse (GEK), a statutory health in-
surance company which insured 1.7 million people lo-
cated in all regions of Germany during the study period
(2% of the German population). The data used in this
study are not publicly available. Patients with a first
diagnosis of dementia in ambulatory medical care be-
tween the first quarter of the year 2005 and the first
quarter of 2006 were identified. Quarters had to be
chosen because they form the basic time period for cod-
ing diagnoses in ambulatory care in Germany and only
the quarter in which a diagnosis occurred is available in
claims data. Patients with incident dementia were in-
cluded if the following criteria were fulfilled:
 age of at least 65 years,
 at least one ICD-10 code for dementia from the
following list (F00.x, F01.x, F02.0, F02.3, F03,
G30.x, G31.0, G31.1, G31.82, G31.9, and R54) in
ambulatory medical care in at least 3 of 4
consecutive quarters,
 at least 4 quarters free from this diagnoses
before and
 continuous insurance period of four quarters before
and after the first code was recorded.Furthermore, we matched up to four controls for
each patient with incident dementia using the nearest
neighbour matching method of the matchit package of
the statistical software ‘R’. Matching criteria were sex,
year of birth, amount of contacts with physicians, and
the number of consulted physicians four quarters be-
fore incidence. Thus patients with and without demen-
tia are comparable with regard to ambulatory health
care utilisation. Further requirements for the control
group were the absence of dementia diagnoses and a
continuous insurance period within the 2 years of ob-
servation. The quarter in which one of the codes indi-
cating dementia appears for the first time is called the
‘incidence quarter’. The incidence quarter of the con-
trols was that of the case. This and the following 3
quarters are referred to as the ‘incidence year’, forming
the study period for all of our following analyses.
The selection of patients and controls has been de-
scribed in more detail elsewhere [19-21].Diagnoses indicating pain, analgesic prescribing
and covariates
The International Classification of Diseases (ICD-10)
lists only few specific pain diagnoses. Thus, relying only
on these diagnoses for the identification of patients
with pain in claims data would probably underestimate
its occurrence. Freytag et al. used classification and re-
gression trees (CART) for the identification of patients
with pain based on health insurance claims data [22].
They developed 9 types of pain to which 77.1% of all
patients with at least two opioid prescriptions within a
one year period could be allocated. By aggregating
these 9 pain types and further including unspecific
diagnoses, nearly all persons with at least one prescrip-
tion of tramadol (91.7%) could be identified as patients
with pain in a recent analysis [23]. Based on these stud-
ies we used the following pain types and ICD-10
diagnoses:
 Cancer pain (ICD-10: C20, C34, C64, C77-C80, C85,
C90, Z51),
 Pain due to arthritis or osteoarthritis (ICD-10: M06,
M13, M15-M19, M25),
 Pain due to fractures (ICD-10: S12, S22, S32, S42,
T02, T08, T91),
 Pain due to multimorbidity and care dependency
(ICD-10: L89, L97, L98),
 Headache (ICD-10: G43, G44, R51),
 Neuropathic pain (ICD-10: G50, G54, G56-G58,
G62, G63, M79, M89),
 Back pain (ICD-10: M43, M45-M51, M53, M54,
M81, M82) and
 Pain, not elsewhere classified (ICD-10: R52).
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be documented in ambulatory medical care within the
incidence year, or the respective year in controls.
The prescription of drugs within the German statutory
health insurances is allowed for all physicians (including
general practitioners as well as specialists) working in the
ambulatory sector. The hospital sector does not play a not-
able role in the prescription of drugs. Prescriptions relate
to both community-dwelling persons and those living in
nursing homes. With some exceptions including over-the-
counter (OTC) medications, prescribed drugs are reim-
bursed by the statutory insurances requiring a co-payment
of 10% of the price with a minimum of 5 € and a maximum
of 10 € for each prescription. However, co-payment exemp-
tions are available for the chronically ill.
We identified all drugs according to the so-called anal-
gesic ladder of the World Health Organization (WHO).
However, acetylsalicylic acid (ASA) and paracetamol were
not included in the analyses because both drugs are not
reimbursed by the statutory health insurances and are
solely bought OTC in Germany. We also studied the route
of administration with a special focus on liquid oral and
transdermal formulations.
We used two measures of comorbidity: (1) levels of care
dependency and (2) the number of prescribed medica-
tions. Services from the German long term care insurance
are provided to those who require support in their activ-
ities of daily living including personal hygiene, eating, mo-
bility and – separate from personal care – housekeeping.
There are three levels of care dependency related to the
estimated time required for assistance indicating moderate
(level I), severe (level II) and severest care dependency
(level III) [24,25]. If care dependency changed within the
incidence year we included the highest level in our ana-
lyses. Furthermore, it has been shown that the number of
distinct medications prescribed performed well as a pre-
dictor for health services utilization and mortality in older
persons [26,27]. This easily applicable measure of degree
of comorbidity is often used in studies based on claims
data [28,29]. For our analyses, we categorised the number
of prescribed medications within the incidence year into
quartiles (including all prescriptions filled in pharmacies).
Statistical analysis
Our main focus lies on differences between patients with
and without dementia. After a descriptive characterisation
of the study cohort, the proportion of patients with at least
one diagnosis indicating pain in the incidence year of de-
mentia or the respective year in those without dementia
was estimated. We further compared the agents prescribed
to the two groups within the incidence year. The propor-
tions of patients prescribed analgesics were compared on
the basis of at least one prescription per patient. We
grouped analgesics according to the WHO analgesic ladderas well as to the route of administration. Differences in
proportions between the dementia and control group were
analysed with the chi-square test.
To study the relation between the prescription of at least
one analgesic drug and incident dementia, we fitted logistic
regression models and stepwise adjusted for several covari-
ates. First, an univariate analysis was performed (model 1).
In model 2, we adjusted for demographic variables and care
dependency including age (65–74, 75–84, 85+ years); sex
(male, female); level of care dependency (4 categories) and
place of residence (nursing home, community-dwelling).
For model 3, further comorbidity measures and diagnoses
indicating pain were entered in the multivariate model: the
quartiles of the numbers of prescribed medications (4 cat-
egories) as a proxy for the severity of comorbidity as well as
the 8 different pain types (yes, no). Crude and adjusted
odds ratios (OR) with 95% confidence intervals (95% CI)
were estimated.
We performed all statistical analyses with SAS for
Windows version 9.2 (SAS Institute Inc., Cary, NC).
The study was conducted according to the principles
expressed in the Declaration of Helsinki. The use of health
insurance claims data for scientific research is regulated by
the German Code of Social Law (SGB X) and no informed
consent has to be obtained. According to the Good Practice
of Secondary Data Analysis, a national guideline for the use
of administrative databases, no approval of an ethical com-
mittee is required [30].
Results
Characteristics of the study cohort
Baseline characteristics of the 1,848 patients with demen-
tia and 7,385 controls are shown in Table 1. Because of
the matching, sex and age are similar in both cohorts, but
there are noticeable differences regarding care depend-
ency. Almost half of the dementia patients (44.4%) are
assigned to one of the three care levels within the inci-
dence year, whereas this proportion is only 12.9% for the
control group. Patients with dementia received on average
more different medications than controls (9.7 vs. 7.6).
Although there are pain types from which patients with
dementia suffer more often than controls (for instance,
pain due to fractures and pain due to multimorbidity and
care dependency), the proportion of patients receiving at
least one diagnosis indicating pain is similar in both
groups (74.4% vs. 72.5%; p = 0.11) (Table 2).
Prescribing of analgesic drugs
A total of 18,868 dispensings of analgesic drugs were in-
cluded in the analyses. The top ten most frequently used
substances in the dementia and control group are shown in
Table 3. Noticeably, the top five substances already make
up more than three quarters of the prescriptions in both
groups. Metamizole (27.4% vs. 17.8%) and tramadol (13.5%
Table 1 Baseline characteristics of patients with incident
dementia and matched controls
Baseline characteristics Dementia
group (n = 1,848)
Control
group (n = 7,385)
Mean age, in years (SD) 78.7 (7.4) 78.7 (7.4)

















9.7 (5.7) 7.6 (5.4)
25th percentile (Q1) 6 4
50th percentile (Q2) 9 7
75th percentile (Q3) 13 11
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scriptions in patients with dementia while diclofenac
(mono) (18.9% vs. 26.3%) and tilidine/naloxone (6.0%
vs. 7.9%) were more often prescribed for controls (p <
0.0001 for all comparisons).Table 2 Types of pain in patients with incident dementia
and matched controls









Back pain 51.7 53.2 0.23
Pain due to arthritis
or osteoarthritis
41.2 41.8 0.64
Neuropathic pain 19.4 16.5 0.0037
Pain due to fractures 4.6 3.0 0.0006
Pain due to multimorbidity
and care dependency
9.8 4.0 <0.0001
Pain, not elsewhere classified 9.0 6.0 <0.0001
Headache 6.3 5.0 0.0331
Cancer pain 5.0 5.9 0.14
Total (at least one pain type) 74.4 72.5 0.11The proportion of patients with at least one analgesic
drug prescription during the incidence year was signifi-
cantly higher in patients with dementia compared to con-
trols (47.5% vs. 44.7%; p = 0.03). This difference is mainly
due to a higher prescription prevalence with WHO step II
opioids and liquid oral substances in the dementia group
(Table 4). Again, more patients with dementia received
metamizole (18.7% vs. 12.8%) and tramadol (8.8% vs. 6.0%).
Both agents are available in liquid oral formulations in
Germany. Also, significantly more patients with dementia
got prescriptions for transdermal opioids, but the overall
prevalence is relatively low.
Factors associated with prescribing
Results of the univariate and multivariate logistic regres-
sion analyses are presented in Table 5. As reported
above, significantly more patients with dementia re-
ceived prescriptions of analgesics in the crude analysis.
However, this association was no longer found when we
adjusted for age, sex, level of care and place of residence
in model 2 (OR: 0.96; 95% CI: 0.86-1.07). After including
the number of prescribed medications as a comorbidity
measure as well as diagnoses indicating pain (model 3), we
found that analgesics were significantly less often pre-
scribed for patients with dementia (OR: 0.78; 95% CI:
0.68-0.88). Female sex and long-term care level II (but not
level III) were associated with prescriptions of analgesics
in both models and the number of prescribed medications
showed a strong impact whereas place of residence had no
influence. Within the types of pain investigated, pain due
to osteoarthritis, fractures, neuropathic pain and back pain
showed statistically significant associations with prescrip-
tions of analgesics in the multivariate model.
Discussion
Findings, comparison with other studies
and interpretation
We found several interesting results. Diagnoses indicating
pain during the year of observation were highly prevalent
with no difference between patients with a first diagnosis
of dementia and controls. This was also the case when we
adjusted for all other covariates in a multivariate analysis
(data not shown). This finding might contradict the wide-
spread perception that pain or conditions associated with
it often remain undetected in dementia [5-8]. However,
pain management still seems to receive less attention in
patients with dementia, which is also suggested by a recent
study of nursing home residents [13]. Although the prob-
ability of receiving at least one analgesic drug was slightly
higher for patients with incident dementia in our crude
analysis, the results of the adjusted logistic regression
show a significantly lower chance for patients with demen-
tia, when controlled for diagnoses indicating pain and co-
morbidity. Interestingly, this result still remains significant
Table 3 Top ten most prescribed analgesic drugs for patients with incident dementia and matched controls
Dementia group (n = 1,848; 4,441 prescriptions) Control group (n = 7,385; 14,427 prescriptions)
Substance Proportion (in %) Substance Proportion (in %)
Metamizole (dipyrone) 27.4 Diclofenac (mono) 26.3
Diclofenac (mono) 18.9 Metamizole (dipyrone) 17.8
Tramadol 13.5 Ibuprofen 13.3
Ibuprofen 12.5 Tramadol 10.2
Fentanyl 6.7 Tilidine/naloxone 7.9
Tilidine/naloxone 6.0 Fentanyl 6.3
Oxycodone 1.8 Oxycodone 2.1
Codeine/paracetamol 1.8 Codeine/paracetamol 2.1
Buprenorphine 1.7 Morphine 2.0
Flupirtine 1.6 Buprenorphine 1.7
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excluding antidementia drugs as well as analgesics from
the number of prescribed medications in model 3 (data
not shown), underlining the robustness of our findings.
Therefore, we can conclude that drug treatment is often
not initiated for some dementia cases. We also found that
the proportion of patients with diagnoses indicating pain
was much higher than the proportion of patients with an-
algesic prescriptions in dementia (74.4% vs. 47.5%) as well
as in controls (72.5% vs. 44.7%). An awareness/recognition
problem might be an explanation for this finding. OurTable 4 Proportion of patients receiving a prescription
for at least one analgesic drug according to WHO ladder
and route of administration for patients with incident










WHO step I drugs
Diclofenac (mono) 19.5 21.6 0.04
Metamizole 18.7 12.8 <0.0001
Total 42.8 40.7 0.11
WHO step II drugs
Tramadol 8.8 6.0 <0.0001
Tilidine/naloxone 4.1 3.9 0.77
Total 14.7 11.4 0.0001
WHO step III drugs
Fentanyl 2.5 2.0 0.16
Oxycodone 0.8 0.9 0.65
Total 4.2 3.6 0.19
Route of administration
Liquid oral 19.2 12.8 <0.0001
Transdermal 3.1 2.3 0.03
Total (at least one analgesic) 47.5 44.7 0.03results further emphasize that comorbidities should be
taken into account when prescription patterns are com-
pared between patients with and without dementia.
In contrast to other studies examining the treatment of
dementia patients with analgesics [8-16], we investigated a
sample with a first diagnosis of dementia. We rather had
expected not to find any differences in analgesic prescrip-
tions between patients with and without dementia in this
sample, as communication might not be heavily impaired
at this stage. Our findings raise the question if differences
in pain medication will become even more apparent with
the progression of the disease. This longitudinal perspec-
tive should be considered in further research.
Previous efforts to improve the management of pain in
patients with dementia focused on recommendations for a
better detection of pain by physical examination and the
assessment of pain using self-report and observational
methods [31,32]. In our study, dementia patients were
given less pain medication despite comparable pain related
diagnoses. This result suggests that in addition to the diffi-
culties in pain recognition, other factors may influence the
decision to start pain medication in patients with demen-
tia. The results of the logistic regression analysis revealed
that women, patients with long term care dependency
level II, patients with greater comorbidity and pain related
to musculoskeletal problems had a greater chance of being
prescribed analgesic drugs. Patients with more comorbidi-
ties use more medications and receive more often pre-
scriptions of analgesics. A further interpretation might be
that pain medication is often prescribed to control pain in
the context of mobility. If mobilization is not a primary
goal any more, as this is often the case in long term care
level III, this can lead to a justified or unjustified reduction
of pain medication. Pokela et al. reported a similar associ-
ation between self-reported mobility and analgesic use in
older persons [33]. Studies investigating differences in
other medications between patients with and without de-
mentia discussed further explanations for undertreatment:
Table 5 Logistic regression of factors associated with at















0.96 (0.86-1.07) 0.78 (0.68-0.88)
Female sex
(vs. male)




75-84 1.09 (0.99-1.20) 0.96 (0.86-1.07)
85+ 1.10 (0.97-1.24) 1.10 (0.96-1.27)
Level of long term care
None 1 1
I 1.46 (1.25-1.70) 1.08 (0.91-1.30)
II 1.69 (1.40-2.03) 1.30 (1.05-1.62)
III 1.26 (0.91-1.76) 1.06 (0.73-1.55)
Nursing home residence
(vs. community-dwelling)




Q2 (5–7) 2.22 (1.94-2.54)
Q3 (8–11) 3.79 (3.31-4.34)
Q4 (12–51) 7.65 (6.58-8.89)
Cancer pain (vs. no) 1.08 (0.88-1.32)
Pain due to arthritis or
osteoarthritis (vs. no)
2.39 (2.17-2.64)


















OR = Odds Ratio; CI = Confidence Intervals; Q1, Q2, Q3, Q4 = 25th, 50th, 75th
and 100th percentile.
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cular diseases in patients with dementia, especially a less
frequent treatment with antithrombotic agents in stroke
and beta-blockers in case of hypertension [34]. They for-
warded that caution may be an explanation, as older sub-
jects with dementia are known to have an increased risk of
falls leading to trauma. In an exploratory German study,Müther et al. found inconclusive results when comparing
medications for diabetes, hypertension or hyperlipidemia
in patients with dementia compared to controls [35].
There were noticeable differences in the prescribing
habits of analgesics between the two groups with liquid
oral substances like metamizole and tramadol as well as
transdermal opioids more often used in dementia. The lat-
ter finding is in line with the study of Bell et al. [18]. Al-
though morphine, oxycodone, or hydromorphone given
by the oral route are recommended as first choice step III
opioids, transdermal fentanyl and buprenorphine are alter-
natives for patients with swallowing problems [36], as in
some cases of advanced dementia. However, transdermal
fentanyl is also often used as a first-line step III opioid in
patients without these diagnoses in Germany [37]. The
frequent use of liquid oral substances and especially meta-
mizole might also be related to swallowing problems in
dementia patients. However, metamizole is associated with
potentially life-threatening agranulocytosis [38,39] and
caution is indicated, particularly when prescribed over
long periods.
Strengths and limitations
Using claims data for research has many advantages but
also disadvantages. On the one hand selection bias is re-
duced, as claims data allow us to study diagnoses indicat-
ing pain and analgesics prescriptions in dementia patients
irrespective of their current state of health, communica-
tion problems, old age, frailty, institutionalisation or loca-
tion. Also we could control for further patient related
factors such as level of care dependency, and the number
of prescribed medications as comorbidity measures.
On the other hand, validity of diagnoses should be con-
sidered [40]. Although we studied newly diagnosed pa-
tients, we know that the coding of dementia diagnoses is
made rather late due to taboo, stigmatization, difficulty in
the diagnostic process, and poor therapeutic options
[41-43]. Therefore, our sample may partially consist of pa-
tients in more advanced stages of dementia. This is also
suggested by the fact that 24% of the incident cases were
already assigned to care levels II and III. We also did not
distinguish between different types of dementia as within
our data set more than half of the coded dementia diagno-
ses are F03, unspecified dementia. This is probably due to
the fact that a more precise diagnosis is not needed for re-
imbursement issues, the primary function of claims data.
However, pain identification and management of pain
should not be severely impaired by the absence of a pre-
cise etiological dementia diagnosis. In Germany, validation
studies are scarce [40] and no data on the validity of the
dementia diagnosis as well as of the types of pain are
available.
It should further be kept in mind that we analyzed diag-
noses indicating pain and not pain itself. We do not know
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analgesics were prescribed. Therefore, it was not possible
to study the quality of analgesic prescribing and we only
used the indicator ‘at least one analgesic’. Furthermore, we
do not know whether drugs were prescribed as perman-
ent, acute or as-needed medication, which could be rele-
vant in the case of pain medication [16]. Paracetamol is
one of the most used analgesics and in some studies more
frequently used in patients with than in those without de-
mentia [15,17]. Unfortunately we could not analyze its use
as it is an OTC drug and not documented in claims data.
Some of the included step I drugs (ibuprofen, naproxen,
diclofenac) are also available as OTC drugs and only reim-
bursed - and thus included in claims data - at higher
doses. For stage II and III analgesics, we are likely to have
a fairly good coverage using claims data. Finally, we used
data of one health insurance fund only and there are dif-
ferences between these funds in Germany, for example
with respect to age, sex, socioeconomic status and mor-
bidity [44,45]. Thus extrapolations of analyses of single
funds to the whole German population should be per-
formed with caution. However, there seems to be no obvi-
ous reason for treatment differences in patients with
dementia between different health insurance funds.Conclusions
Our findings show a comparable documentation of
diagnoses indicating pain in persons with incident de-
mentia compared to those without. However, when tak-
ing comorbidity into account, there still seems to be an
undertreatment of pain in dementia. This might indi-
cate an awareness/recognition problem. Irrespective of
dementia, analgesics seem to be more often prescribed
to sicker patients and to control pain in the context of
mobility. Special attention concerning pain medication
should therefore be paid in immobilized patients, as
immobilization can lead to a (justified or not) reduction
of pain medication. Prescription of analgesics in trans-
dermal or liquids forms may be alternatives in demen-
ted patients who suffer from swallowing disorders, but
might cause other problems. Our findings raise the
question what further reasons might lead to the under-
treatment of pain in dementia and what changes occur
in the progression of the disease. This longitudinal per-
spective should be taken up in further research.Competing interests
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